Proteome Sciences plc (AIM:PRM)

Market Cap	9.77M
Revenue (ttm)	4.89M
Net Income (ttm)	-3.41M
Shares Out	295.18M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,200,000
Average Volume	227,210
Open	3.040
Previous Close	3.470
Day's Range	3.040 - 3.500
52-Week Range	2.220 - 5.400
Beta	0.02
RSI	55.30
Earnings Date	Aug 4, 2025

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling p...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1993
• Employees: 36
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PRM

Financial Performance

In 2024, Proteome Sciences's revenue was 4.89 million, a decrease of -2.80% compared to the previous year's 5.03 million. Losses were -3.41 million, 39.4% more than in 2023.